deltatrials
Terminated PHASE1 NCT00249301

A Study of MLN8054 in Patients With Advanced Solid Tumors

An Open-Label, Dose Escalation Phase 1 Study of MLN8054, a Novel Aurora A Kinase Inhibitor, in Patients With Advanced Solid Tumors

Sponsor: Millennium Pharmaceuticals, Inc.

Conditions Bladder Neoplasm Breast Neoplasm Colon Neoplasm Pancreatic Neoplasm
Interventions MLN8054
Updated 6 times since 2017 Last updated: Mar 28, 2008 Started: Oct 31, 2005 Primary completion: Jan 31, 2008

A PHASE1 clinical study on Bladder Neoplasm and Breast Neoplasm, this trial is terminated or withdrawn. The trial is conducted by Millennium Pharmaceuticals, Inc. and has accumulated 6 data snapshots since 2005. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1

  3. Jan 2021 — Jul 2024 [monthly]

    Terminated PHASE1

  4. Jun 2018 — Jan 2021 [monthly]

    Terminated PHASE1

  5. Feb 2017 — Jun 2018 [monthly]

    Terminated PHASE1

▶ Show 1 earlier version

  1. Jan 2017 — Feb 2017 [monthly]

    Terminated PHASE1

    First recorded

Oct 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Millennium Pharmaceuticals, Inc.
Data source: Millennium Pharmaceuticals, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Nashville, United States